MX2022003051A - Formulaciones para la administracion de farmacos. - Google Patents

Formulaciones para la administracion de farmacos.

Info

Publication number
MX2022003051A
MX2022003051A MX2022003051A MX2022003051A MX2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A
Authority
MX
Mexico
Prior art keywords
drug delivery
delivery formulations
risperidone
triblock
disorders
Prior art date
Application number
MX2022003051A
Other languages
English (en)
Inventor
Christophe Roberge
Anthony Rech
Eran Harary
Original Assignee
Medincell S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell S A filed Critical Medincell S A
Publication of MX2022003051A publication Critical patent/MX2022003051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se dirige a métodos de tratamiento de enfermedades y trastornos psiquiátricos que comprenden la administración a un sujeto que lo necesita de una formulación inyectable que comprende risperidona, copolímeros tribloque y dibloque, en donde la concentración de la risperidona es de 250-400 mg/mL y el volumen de inyección es de 1 mL o menos.
MX2022003051A 2019-09-13 2020-09-11 Formulaciones para la administracion de farmacos. MX2022003051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900061P 2019-09-13 2019-09-13
PCT/IB2020/058474 WO2021048817A1 (en) 2019-09-13 2020-09-11 Drug delivery formulations

Publications (1)

Publication Number Publication Date
MX2022003051A true MX2022003051A (es) 2022-06-14

Family

ID=72521677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003051A MX2022003051A (es) 2019-09-13 2020-09-11 Formulaciones para la administracion de farmacos.

Country Status (11)

Country Link
US (2) US20220331240A1 (es)
EP (1) EP4027973A1 (es)
JP (1) JP2022548616A (es)
KR (1) KR20220062372A (es)
CN (1) CN114727946A (es)
AU (1) AU2020346455A1 (es)
BR (1) BR112022004535A2 (es)
CA (1) CA3153793A1 (es)
IL (1) IL291283A (es)
MX (1) MX2022003051A (es)
WO (1) WO2021048817A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240148641A1 (en) * 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022708A (ko) * 1997-08-08 2001-03-26 프레드한 아룬디프 에스 약물 수송에 이용할 수 있는 생분해가능한 주사용 블록공중합체 겔
CN101584652B (zh) * 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
LT2658525T (lt) * 2010-12-29 2017-12-11 Medincell Biologiškai skaidomos vaistų tiekimo kompozicijos
MX350469B (es) * 2011-10-24 2017-09-07 Endo Pharmaceuticals Solutions Composiciones para el suministro de farmacos implantables y metodos para su tratamiento.
CA2877083C (en) * 2012-06-27 2020-10-06 Medincell Biodegradable drug delivery for hydrophobic compositions
AU2014249008B2 (en) * 2013-03-11 2018-12-06 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
WO2019016233A1 (en) * 2017-07-17 2019-01-24 Medincell PHARMACEUTICAL COMPOSITION

Also Published As

Publication number Publication date
CN114727946A (zh) 2022-07-08
IL291283A (en) 2022-05-01
CA3153793A1 (en) 2021-03-18
US20220331240A1 (en) 2022-10-20
JP2022548616A (ja) 2022-11-21
EP4027973A1 (en) 2022-07-20
AU2020346455A1 (en) 2022-03-31
BR112022004535A2 (pt) 2022-06-07
KR20220062372A (ko) 2022-05-16
US20240156722A1 (en) 2024-05-16
WO2021048817A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
LUC00011I1 (es)
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
WO2010123569A3 (en) Immunonanotherapeutics providing a th1-biased response
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
WO2014160155A3 (en) Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
MX2022003051A (es) Formulaciones para la administracion de farmacos.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2021011727A (es) Composiciones y metodos para tratar enfermedades oculares.
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
MX2023010925A (es) Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
NZ760033A (en) Methods to treat opioid use disorder
MX2020006886A (es) Sistema para suministro de medicamento.
EA201590323A1 (ru) Способ введения активных веществ в головной мозг
MX2023005398A (es) Formulaciones, metodos, kits y formas de dosificacion.